<DOC>
	<DOC>NCT00942994</DOC>
	<brief_summary>The purpose of the study is to compare the combination of aliskiren, amlodipine and Hydrochlorothiazide (HCTZ) versus the combination of aliskiren and amlodipine as therapy in minority Stage 2 hypertensive patients.</brief_summary>
	<brief_title>Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Patients who are newly diagnosed or have a history of hypertension, who are eligible and able to participate in the study, and who give written informed consent before any assessment is performed. Men or women 18 years and older of minority background; selfidentified. Patients with stage 2 hypertension defined as MSSBP ≥160 mmHg and &lt;200 mmHg at Visit 5 (randomization). Patients with MSDBP ≥110 mmHg and/or MSSBP ≥200 mmHg as measured by office cuff at any visit. Patients on 4 or more antihypertensive medications. Patients with uncontrolled hypertension (MSSBP &gt;180 mmHg) taking more than 1 antihypertensive medication at Visit 1.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Aliskiren</keyword>
	<keyword>Amlodipine</keyword>
	<keyword>HCTZ</keyword>
	<keyword>Systolic blood pressure</keyword>
	<keyword>Diastolic blood pressure</keyword>
	<keyword>Stage II</keyword>
	<keyword>Combination</keyword>
</DOC>